Physician profile

Anju Ohri

Hematology & Oncology · Manhasset, NY

NPI 1902833304

$1,460.01

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

See the full distribution for Hematology & Oncology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$274.76

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $496.47 2019-2023 Shingrix
Abbott Laboratories $317.53 2021-2024 Freestyle Libre 3
Janssen Biotech, INC. $178.99 2019-2022
Boston Scientific Corporation $125.63 2022
Insmed, INC. $121.34 2021
Astrazeneca Pharmaceuticals LP $87.50 2022
Gilead Sciences, INC. $83.63 2019
Celgene Corporation $24.68 2022
Melinta Therapeutics, LLC $24.24 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anju Ohri

$1,460.01

in general payments reported 2019-2025

Years
2019-2024
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/40399/anju-ohri

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.